PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 139 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 2.23 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $362,740 | -92.0% | 21,747 | -86.8% | 0.00% | -88.9% |
| Q2 2023 | $4,543,489 | -85.5% | 164,500 | -88.0% | 0.01% | -86.6% |
| Q1 2023 | $31,419,840 | +98.0% | 1,366,080 | -6.1% | 0.07% | +86.1% |
| Q4 2022 | $15,868,006 | +131.0% | 1,454,446 | +78.5% | 0.04% | +140.0% |
| Q3 2022 | $6,869,000 | +87.1% | 814,726 | +75.6% | 0.02% | +87.5% |
| Q2 2022 | $3,671,000 | +63.5% | 464,057 | +435.3% | 0.01% | -20.0% |
| Q1 2021 | $2,245,000 | -4.6% | 86,691 | -25.8% | 0.01% | -23.1% |
| Q4 2020 | $2,354,000 | +989.8% | 116,794 | +556.2% | 0.01% | +550.0% |
| Q2 2019 | $216,000 | – | 17,799 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |